Pacira Biosciences: Truist Securities raises target price to $31 from $30
PCRX•Truist Securities raised its target price for Pacira Biosciences to $31 from $30.
Related News
Helmerich & Payne sees fiscal Q4 direct margins near high end of guidance
HP•
PROG Holdings to release third-quarter 2026 results
PRG•
Safe Pro expects Q3 2026 revenue to top $2.5 million, up more than 2,300% year over year
SPAI•
Maia Biotech completes enrollment for THIO-101 Phase 2 NSCLC trial of ateganosine plus cemiplimab
MAIA•
Trulieve repays about $65 million mortgage notes payable early
TCNNF•